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 Abstract 
A recent revision to the European Medical Device Directive (MDD 2007/47/EC) made fourteen 
amendments to the original directive (93/42/EEC). A number of these changes directly affect the de-
velopment of software for use in healthcare. The most significant change in relation to medical device 
software development is that standalone software is now seen as an active medical device. Prior to 
this amendment medical device software was developed in accordance with the IEC 62304 standard. 
However, IEC 62304 is not sufficiently comprehensive to provide guidance in the development of 
standalone software as an active medical device. Medi SPICE is currently being developed to fill the 
gaps left by IEC 62304 in developing standalone software as an active medical device and to provide 
medical device software developers a single point of reference for developing software for use in 
healthcare. 
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1 Introduction 
Software is ubiquitous in daily life however, it is more critical in some areas than others. Failures in 
medical device software can have severe or fatal consequences. Between June 1985 and January 
1987, four people died and two were left permanently disfigured  by a software controlled radiation 
therapy machine known as Therac-25[1]. Therac-25 used software to control a beam spreader plate 
which reduced patient’s exposure to radiation. However, due to software malfunctions the plate was 
not in place when required and patients received massive doses of radiation.  This case highlighted 
the need for adequate safety measures to be put in place to protect patients and third parties i.e. clini-
cians, using medical devices controlled by software.  
   All medical devices used within the European Union (EU) must conform to the current MDD 
to achieve the CE conformance mark. The current directive i.e. 2007/47/EC[2], amends European 
directives MDD (93/42/EEC)[3], AIMD (90/385/EEC)[4] and the  Biocides Directive (98/8/EC)[5] [6]. 
The revision to the MDD (2007/47/EC) covers all areas relevant to medical devices including risk and 
quality management. This latest amendment allows for standalone software to be used as an active 
medical device. With this amendment, incidents involving medical devices such as Therac-25 become 
more relevant, as now software can be the only element in a medical device subject to conformance 
requirements.  
How amendments to the Medical Device 
Directive affect the Development of Medi-
cal Device Software 
Martin Mc Hugh, Fergal Mc Caffery, Valentine Casey 
Regulated Software Research Group 
Dundalk Institute of Technology 
martin.mchugh@dkit.ie, fergal.mccaffery@dkit.ie, valentine.casey@dkit.ie 
 Consequently methods used to ensure that software is safe and fit for purpose must be re-
viewed. A number of benefits can be gained by manufacturers employing Software Process Improve-
ment (SPI) techniques, one of which is a reduction in software faults that could potentially result in 
device recalls [7]. SPI is a continuous cycle of performing an assessment, implementing the recom-
mendations of the assessment and restarting the cycle [8]. This process of continuous assessment 
and improvement can help reduce the amount of defective software being developed. Essentially the 
safety of medical device software is determined through the software processes followed during de-
velopment [9]. 
 IEC 62304[10] is the current medical software lifecycle process standard. This standard con-
tains a number of processes for medical device software development which medical device software 
developers should follow in order to implement best practice medical device software processes. IEC 
62304 is used in the development of software when software is part of a medical device system which 
consists of hardware plus software. It provides the minimum regulatory medical device requirements 
within a specified group of processes. However, it excludes all system level processes. As a result, 
IEC 62304 hands off the  system processes to other standards such as ISO 13485[11], IEC 60601-
1[12], IEC 61010-1[13], IEC/ISO 90003[14], IEC 61508-3 [15], ISO 14971 [16] and ISO 12207[17] [10].  
 Section 2 examines the revision to the MDD and highlights what this means with respect to 
medical device software development. This will include particular reference to the development of 
standalone software as an active medical device. In section 3, we discuss the existing standards that 
are appropriate to the development of medical devices with emphasis on satisfying the requirements 
of the MDD (2007/47/EC). In section 4, we discuss the importance of SPI techniques and recommend 
a specific SPI model to follow. Section 5 contains the conclusions from this research and our plans to 
progress this research further. 
2 European Medical Device Directive Amendment 2007/47/EC 
The recent MDD [2] revision has made a number of amendments to previous directives i.e. [3-5].The 
MDD (2007/47/EC) came into force on March 21st 2010. In total there are fourteen changes intro-
duced within the MDD (2007/47/EC)[18]. There are four areas within the amendment of the MDD 
(2007/47/EC) with important significance to medical device software development: 
 
? Standalone Software as an active medical device; 
? Validation of software as an active medical device; 
? Software localisation; 
? Safety Classification. 
2.1 Standalone Software as an Active Medical Device 
Prior to the release of the MDD (2007/47/EC) provision had been made within the MDD (93/42/EEC) 
for software to be used as a medical device. However MDD (2007/47/EC) Article 1 Section 2 makes 
explicit reference to software being a medical device. 
  
“any instrument, apparatus, appliance, software, material or other article, whether used alone or in 
combination, including the software intended by its manufacturer to be used specifically for diagnostic 
and/or therapeutic purposes and necessary for its proper application” 
 
To accompany this change provision has also been made for standalone software to be used as an 
active medical device. Within the MDD (2007/47/EC) Annex IX Section 1.4 amendment M5 states: 
 
“Stand-alone software is considered to be an active medical device” 
 
This can be difficult to understand particularly in relation to when software is or is not a medical de-
vice. An example of software as an active medical device is a software package which is used to cal-
culate treatment doses for oncology treatment devices. A caveat has also been included into MDD 
(2007/47/EC) to avoid ambiguity in determining if a software package is a medical device. 
 
“software for general purpose when used in a healthcare setting is not a medical device” 
 
This caveat provides some clarity surrounding particular software used in healthcare. In Ireland we 
await a formal document from the Irish Medicines Board to define exactly what types of healthcare 
software applications will now be defined as a medical device. This document is expected in the spring 
of 2011 but in its absence there is still some confusion regarding what standalone software will be 
classified as a medical device. 
2.2 Software Validation 
As standalone software is now classified as an active medical device under the MDD (2007/47/EC) 
guidelines must be put in place to ensure that such software is safe and fit for purpose. To ensure this 
the MDD (2007/47/EC) Annex I Section 12.1a (amendment M5) states; 
 
“For devices which incorporate software or which are medical software in themselves, the software 
must be validated according to the state of the art taking into account the principles of development 
lifecycle, risk management, validation and verification.” 
 
“State of the Art” is used to here to mean what is generally accepted as good practice. Since this re-
quirement was introduced, developers must now validate the software integrated or standalone, re-
gardless of device class. IEC 62304 and its aligned, standards, ISO 13485, IEC 62366 [19], IEC\TR 
80002-1 [20], 80001-1 [21], EN 60601 and ISO 14971 are  harmonised under the MDD (2007/47/EC) 
and are seen as a good place to start when validating software.   
 Whilst these standards are generally accepted and are harmonised under MDD (2007/47/EC) 
they do not necessarily cover the requirements introduced within the MDD (2007/47/EC). 
2.3 Software Localisation 
Another change which affects the development of medical device software is software localisation. 
Under the MDD (2007/47/EC), software sold or used within the EU must be localised into the lan-
guage of each of the EU countries that the product will be marketed i.e. MDD 2007/47/EC, Article 4.4. 
Essentially, if an Irish medical device manufacturer wishes to market a medical device into France, the 
graphical user interface (GUI) must be available in French. A number of difficulties can arise when 
attempting to perform a software translation [22]: 
 
? Differing file formats; 
? Different character encoding; 
? Character size constraints; 
? Parsing may be required; 
? Errors caused in code caused by repossessing. 
 
There are currently a number of organisations that provide translation services to medical device 
manufacturers such as Global Translations [23]. 
3 IEC 62304 – Software Lifecycle Processes 
Medical device manufactures wishing to achieve regulatory conformance are advised to follow the 
relevant applicable standards. Evidence of following the applicable standards can improve the process 
of achieving regulatory conformance. Medical device software developers typically follow IEC 62304 
and its aligned standards. 
3.1 Processes  
IEC 62304 is a medical device software development standard. It was created to provide assistance in 
terms of the safe design and maintenance of medical device software. Software developed using the 
IEC 62304 standard is founded upon the assumption that the software is developed in accordance 
with a quality management standard (ISO 13485), a risk management standard (ISO/IEC 14971) and 
a product level standard (EN 60601-1). This standard provides a framework of processes divided into 
activities which are further divided into tasks.  
IEC 62304 provides guidance on the development of software as part of a medical device. 
However IEC 62304 does not provide guidance on all of the necessary processes required to develop 
standalone software as an active medical device. IEC 62304 states; 
 
“This standard does not cover validation and final release of the medical device, even when the medi-
cal device consists entirely of software” 
 
With the MDD revision i.e. (2007/47/EC) a medical device can consist only of software. As validation is 
required to ensure reliability and safety another method of validating standalone software as a medical 
device is required. One suggestion is to modify the scope of EN 60601-1 to include medical software 
systems. Another suggestion is to convert IEC 62304 to a product oriented standard in order to make 
it applicable to standalone software as an active medical device. All of these suggestions have ad-
vantages and disadvantages. A favourable outcome would be for IEC 62304 to remain as a software 
lifecycle standard and that a new standard be developed to specifically facilitate standalone software 
as an active medical device.  
3.2 Safety Classification 
IEC 62304 classifies all software based on the risk posed to the patient or user. The devices are clas-
sified as follows: 
 
? Class A: No injury or damage to health is possible 
? Class B: Non-serious injury is possible 
? Class C: Death or Serious Injury is possible 
This classification is similar to that of ISO 14971 Clause 4.4, 5 and 6.1. Safety critical software sys-
tems can be divided into items running a different software element each with its own safety classifica-
tion. These items can be further sub divided into additional software elements. The overall software 
system assumes the highest classification contained within all of the software elements. For example 
if a software system contains five software elements, four of which may be classified as Class A, but 
one may be classified as Class C and therefore the overall device receives a classification of Class C. 
This can be seen in figure 1.0   
 
 
Figure 1.0 Classification of software items within complete software system 
 
 
 
4 SPI and Medi SPICE  
4.1 Importance of SPI 
SPI is an important element within any software development lifecycle. Many organisations have diffi-
culty in consistently developing high quality software. There are many benefits to be gained by using 
SPI including [24]: 
 
? Improvements to overall quality 
? Increased on-time delivery 
? Budget consistency 
? Reduced development costs 
 
SPI places the emphasis on defining processes that are appropriate to the project and ensures that 
these processes are consistently followed. SPI maturity models focus on what has to be done, rather 
than how it should be done. The benefits of utilising SPI can be seen in many companies e.g. Sie-
mens[25], Alcatel [26], NASA[27] and Motorola[28]. 
 In order for SPI to be successful within an organisation, it relies on a number of critical factors. 
In 2005 a survey of one hundred and twenty software organisations identified six organisational fac-
tors as being crucial to ensure the success of SPI [29]: 
 
? Business orientation; 
? Involved leadership; 
? Employee participation; 
? Concern for measurement; 
? Exploitation of existing knowledge; 
? Exploration of new knowledge. 
 
Research carried out by Embedded Market Forecasters in 2010[30]  provided a comparison between 
software developed by the embedded industry and software developed by medical device producers. 
This research showed that 12.9% of medical device projects were cancelled, whilst 11.2% of embed-
ded industry projects were cancelled. This research also revealed that on average 19.4% of the over-
all budget is wasted due to months lost during project development. The primary reason cited for the-
se problems occurring is incomplete or vague requirements.  
 An empirical study in 2007 revealed  how much importance medical device software develop-
ers place upon SPI [31]. The study surveyed organisations developing software for medical devices 
and medical information systems with the majority of respondents coming from Germany, USA and 
Sweden. 71% of respondents came from small and medium companies with between ten and two 
hundred and fifty staff. The remainder of the respondents came from organisations with over two hun-
dred and fifty software developers. Of the respondents, 98% rate software as very important or an 
important part of their products. However, only 14% of the respondents have either a CMMI (Capabil-
ity Maturity Model Integration) or ISO 15504 (SPICE) rating. Also only 50% of the respondents follow a 
defined process to perform requirements engineering, software architecture and design activities and 
implementation, over 50% of the time. This survey also asked participant’s which process or activities 
cause the most issues for a software development project.  
 
 
Figure 2.0 Activities & Processes most difficult to software development projects [31] 
Figure 2.0 shows, the requirements engineering process is seen as causing most of the issues in the 
development of software for medical devices. Typically organisations following a defined set of pro-
cesses or activities contained within an SPI model will have minimal problems with areas such as re-
quirements engineering as they are provided guidance on all areas of development. This survey 
shows an inversely proportional relationship between importance placed on SPI rating/activities and 
difficulties caused by specific process areas.  
Both of these pieces of research [30, 31] show medical device software developers have the 
most difficulties at the requirements elicitation/engineering stage of development.. 
4.2 Medi SPICE  
Currently medical device manufactures developing standalone software as an active medical device 
have no single point of reference specific to the development of software for medical devices. To this 
end Medi SPICE[32] is currently being developed by the Regulated Software Research Group (RSRG) 
at Dundalk Institute of Technology (DkIT) in association with the SPICE User Group, to help in achiev-
ing regulatory conformance and improve overall device safety by employing SPI techniques through 
the entire development lifecycle.  
Medi SPICE provides medical device software manufacturers with a Process Assessment 
Model (PAM), and a Process Reference Model (PRM), to help implement high quality medical device 
software processes that will enable seamless conformity to the medical regulatory standards. The 
PAM is being developed in accordance with the requirements of ISO/IEC 15504-2:2003, and is based 
on ISO/IEC 15504-5:2006. However ISO/IEC 15504 is not specific to the medical device industry. To 
overcome this, Medi SPICE incorporates the practices contained within IEC 62304 processes and the 
other relevant standards into appropriate the relevant ISO/IEC 15504 based processes. Due to the 
safety critical nature of medical device software, additional safety processes have also been incorpo-
rated from +Safe[33] and ISO 14971.     
 Medi SPICE aims to minimise the volume of software documentation and provide global har-
monisation for all medical device software manufactures. Medi SPICE assessment results can be 
used to indicate the state of a medical device supplier’s practice in relation to regulation. Medi SPICE 
results can also be used as a criterion for supplier selection. As discussed in section 4.1 many medical 
device software development companies cite the requirements engineering process as the most prob-
lematic of all of the processes. Medi SPICE will provide clear guidance on how to perform this process 
in addition to other processes of the medical device software development and maintenance lifecycle. 
5 Conclusions 
The recent revision to the MDD allows for standalone software to be an active medical device and 
states that software must be validated in accordance with state of the art practices. However IEC 
62304 does not provide comprehensive guidance on the development of standalone software as an 
active medical device as it is purely a software development standard. An example of a process be-
yond the scope of IEC 62304 is the requirements elicitation stage of development. However research 
has shown that the requirements elicitations stage causes medical device software developers the 
most issues during development. This omission can be overcome by employing an SPI model specific 
in the area of development of medical device software. To this end Medi SPICE is being developed to 
provide guidance in all stages of development of standalone software as an active medical device. 
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